HiFiBiO is advancing an innovative and integrated discovery engine that creates unparalleled opportunities for discovering novel, differentiated therapeutic antibodies against complex targets. The platform combines high throughput, single cell, functional-based screening of entire B cell populations with barcoded next generation sequencing and rapid DNA synthesis to deeply mine tens of millions of B cells in a typical immune response for rare antibody drugs. The multiple, functionally validated and genetically diverse antibodies produced by HiFiBiO’s approach enable the efficient selection of optimal antibody drug leads. The company has entered into multiple antibody discovery collaborations with leading pharmaceutical companies. Visit their site >